Attention: open in a new window. E-mailPrintPDF
In the recent years, Biomed-Lublin was facing financial difficulties due its plasma fractionation project, which exceeded capabilities of the company. However, it seems the most difficult period is now over…

Order subscription to read this article




Order at
Order from our partners:

Call us:

Find us: